Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain
- Jorge Mestre-Ferrándiz; Agustín Rivero; Alejandro Orrico-Sánchez; Álvaro Hidalgo; Fernando Abdalla; Isabel Martín
Access Resources
About
This study evaluates nirsevimab, an antibody-based preventive measure for respiratory syncytial virus (RSV) in Spain. Using a multi-criteria decision analysis framework, experts found that nirsevimab adds value by effectively preventing RSV and potentially reducing hospital costs and health inequities. The study compares it to placebo and palivizumab, highlighting its benefits in broader infant populations with minimal adverse effects. Overall, it suggests that nirsevimab could improve public health awareness about RSV prevention.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.